MannKind Corporation

MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care. It develops and commercializes treatments for serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its key products include Afrezza, an inhaled insulin for adults with diabetes; the V-Go wearable insulin delivery device; Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and FUROSCIX, a furosemide injection for fluid buildup in chronic heart failure or kidney disease. The company also has a pipeline for orphan lung diseases, including MNKD-201 (a dry-powder nintedanib for idiopathic pulmonary fibrosis) and MNKD-701.

MannKind Corporation is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol MNKD. Its financials are reported in US Dollars (USD), as the company is headquartered in the United States. The exchange is a major US stock exchange, providing liquidity and visibility for investors. The currency denomination is important for investors to consider when evaluating financial performance and making investment decisions, as all revenues, expenses, and earnings are in USD.

MannKind Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies for chronic diseases, leveraging advanced drug delivery technologies such as inhalation powders and wearable devices. The biotechnology industry is characterized by high research and development costs, regulatory hurdles, and potential for breakthrough treatments. MannKind's products address diabetes, pulmonary hypertension, and fluid overload, placing it at the intersection of metabolic and respiratory therapeutics.

MannKind Corporation is headquartered in Danbury, Connecticut, United States. The company primarily serves the US market, as its products are approved and marketed in the United States. Its collaboration with United Therapeutics Corporation for Tyvaso DPI also focuses on the US. While the company's description does not specify international markets, its products like Afrezza and V-Go are available to US patients. The company's research and development activities are based in the US, and it leverages partnerships to expand its reach within the country.

MannKind Corporation generates revenue through the sale of its commercial products: Afrezza (inhaled insulin), V-Go (wearable insulin delivery device), Tyvaso DPI (for pulmonary hypertension), and FUROSCIX (furosemide injection). It also earns revenue from collaboration and license agreements, such as its partnership with United Therapeutics Corporation for the development and commercialization of Tyvaso DPI. The company's business model involves developing therapies for chronic conditions with significant unmet needs, often using proprietary drug delivery technologies. Additionally, its pipeline includes treatments for orphan lung diseases, which could provide future revenue streams if approved.